Biotech · Private company · Parsippany, NJ, US
Castle Creek Biosciences, Inc.
SEC CIK 0001756702
Track this companyFree. Adds Castle Creek Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials72 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- D-FiPhase 3 · Dystrophic Epidermolysis BullosaClinicalTrials.gov · fetched Nov 12, 2026
- FCX-007 (dabocemagene autoficel; see below for FCX-007 description)Phase 3 · Recessive Dystrophic Epidermolysis BullosaClinicalTrials.gov · fetched Nov 12, 2026
- Autologous fibroblastsPhase 2 · Restrictive Burn ScarsClinicalTrials.gov · fetched Nov 12, 2026
- Autologous Human Fibroblasts (azficel-T)Phase 2 · Interdental Papillary InsufficiencyClinicalTrials.gov · fetched Nov 12, 2026
- Azficel-T (autologous fibroblasts)Phase 2 · Dysphonia Resulting From Vocal Fold ScarringClinicalTrials.gov · fetched Nov 12, 2026
- FCX-007Phase 2 · Epidermolysis Bullosa Dystrophica, RecessiveClinicalTrials.gov · fetched Nov 12, 2026
- FCX-013Phase 2 · MorpheaClinicalTrials.gov · fetched Nov 12, 2026
- veledimexPhase 2 · MorpheaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Evaluation of D-Fi for the Treatment of Wounds Due to DEBPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 27, 2025ClinicalTrials.gov NCT06892639 · fetched Nov 12, 2026
- A Study of FCX-007 for Recessive Dystrophic Epidermolysis BullosaPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 9, 2020ClinicalTrials.gov NCT04213261 · fetched Nov 12, 2026
- A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)PHASE1_PHASE2 · TERMINATED · started Dec 18, 2019ClinicalTrials.gov NCT03740724 · fetched Nov 12, 2026
- A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)PHASE1_PHASE2 · TERMINATED · started Jul 1, 2016ClinicalTrials.gov NCT02810951 · fetched Nov 12, 2026
- Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related DysphoniaPHASE2 · COMPLETED · started Mar 1, 2014ClinicalTrials.gov NCT02120781 · fetched Nov 12, 2026
- Pilot Study of Azficel-T for the Treatment of Restrictive Burn ScarsPHASE2 · TERMINATED · started May 1, 2013ClinicalTrials.gov NCT01858753 · fetched Nov 12, 2026
- Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary InsufficiencyPHASE2 · COMPLETED · started Jan 1, 2006ClinicalTrials.gov NCT00655889 · fetched Nov 12, 2026